华兰生物：生物药新增长曲线逐渐清晰-20260330

Investment Rating - The report maintains a "Buy" rating for the company [5][7]. Core Insights - The company is expected to experience steady growth in blood products, a gradual recovery in vaccine sales, and rapid growth in biopharmaceuticals, driven by new product launches and clinical advancements [1][5]. - The forecast for 2025 includes revenues of 4.6 billion RMB, with a net profit attributable to the parent company of 940 million RMB, reflecting a 5% increase in revenue but a 14% decrease in net profit year-over-year [1][11]. Revenue Performance - Blood products revenue for 2025 is projected at 3.39 billion RMB, a 4% increase year-over-year, with a gross margin of 50.2%, down 4.2 percentage points year-over-year [2]. - Vaccine revenue is expected to reach 1.2 billion RMB in 2025, marking a 7% year-over-year increase, with a net profit of 180 million RMB, despite an 11% decline in net profit year-over-year [3]. Product Development and Innovation - The company is advancing in various product lines: - Blood products include new processes for IVIG and ongoing clinical trials for FⅨ and SCIG [4]. - Vaccine developments include multiple candidates in different clinical phases, with a focus on flu vaccines and new adjuvants [4]. - Biopharmaceuticals are also progressing, with several products entering late-stage clinical trials [4]. Financial Projections - The company’s net profit forecasts for 2026, 2027, and 2028 are 1.02 billion RMB, 1.14 billion RMB, and 1.27 billion RMB, respectively, reflecting a significant downward adjustment of 40% and 44% for 2026 and 2027 compared to previous estimates [5][12]. - The target price is set at 17.28 RMB, based on a 31x PE ratio for 2026, which is a premium compared to the average PE of comparable companies [5][13].